SOLIGENIX, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SOLIGENIX, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $119.4K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $839.4K | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $948.9K | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $824.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.36M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $4.63M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $5.24M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $5.43M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $10.45M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $8.77M | Mar 27, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $97.3K | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $398.1K | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $95.6K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $538.5K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $1.06M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $643.7K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.12M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $2.02M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $1.89M | Mar 27, 2017 |
| FY2015 | Dec 31, 2014 | $1.73M | Mar 24, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.08M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.27M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($6.14M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($13.80M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($12.55M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($17.69M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($9.36M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($8.90M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($7.15M) | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | ($3.25M) | Mar 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.85M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.44M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.70M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($14.24M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($13.10M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($18.59M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($10.54M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($9.06M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($7.59M) | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | ($5.71M) | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.22M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.31M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $7.94M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $8.19M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $9.80M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $8.12M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $6.75M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $5.51M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $4.30M | Mar 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.27M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.40M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($8.60M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($12.65M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($11.74M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($11.45M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($7.51M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($7.24M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($6.51M) | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | ($4.98M) | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.9K | Mar 31, 2026 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.24M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.97M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $9.80M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $14.28M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $26.87M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $19.89M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $7.78M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $10.49M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $9.55M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $10.27M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.94M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.85M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.27M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $16.75M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $16.15M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $16.15M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $6.32M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $4.21M | Mar 30, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.29M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.12M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $2.52M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($2.47M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2021 | $10.72M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $3.74M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $1.46M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $6.28M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $6.32M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $7.40M | Mar 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($245.05M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($233.97M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($225.70M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($219.56M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($205.77M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($193.21M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($175.53M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($166.17M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($157.27M) | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | ($150.12M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $26.04M | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | $18.68M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.42M | Mar 30, 2021 |
| FY2020 | Dec 31, 2018 | $8.98M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $7.81M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $8.77M | Mar 26, 2019 |
| FY2017 | Dec 31, 2015 | $4.92M | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | $5.53M | Mar 27, 2017 |
| FY2015 | Dec 31, 2013 | $5.86M | Mar 24, 2016 |
| FY2014 | Dec 31, 2012 | $3.36M | Mar 25, 2015 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 21, 2025 |
| FY2024 | Dec 31, 2023 | $1.01M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 15, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (12) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 29, 2022 |
| FY2017 | Dec 31, 2017 | (1) | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | (3) | Mar 27, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 24, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (12) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 29, 2022 |
| FY2017 | Dec 31, 2017 | (1) | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | (1) | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | (3) | Mar 27, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 24, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.09M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 2.51M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 648,761 | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | 2.91M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 2.86M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 30.64M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 21.75M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 17.68M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 8.73M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | 5.47M | Mar 15, 2018 |